AKUMS
DRUGS & PHARMACEUTICALS LTD.
Plot No. 131 to 133, Block-C, Mangolpuri Ind. Area, Phase-I, (Adjoining CBSE Office) Delhi - 110083 (INDIA).
+91-11-69041000 CIN: L24239DL2004PLC125888
www.akums.in
akumsho@akums.net
+91-11-27023256

Ref: Akums/Exchange/2026-27/38

August 08, 2026

To,
The Listing Department
National Stock Exchange of India Ltd.
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051

Symbol: AKUMS

To,
The Listing Department
BSE Limited
25th Floor, New Trading Ring,
Rotunda Building, Phiroze Jeejeebhoy
Towers, Dalal Street, Mumbai – 400 001

Scrip Code: 544222

Sub: Press Release

Respected Sir/Ma'am,

Pursuant to the Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 please find enclosed herewith a copy of press release.

This is for your kind information and records.

Thanking You

Yours Faithfully

For **Akums Drugs and Pharmaceuticals Limited**

Dharamvir Malik
Digitally signed by Dharamvir Malik
Date: 2026.08.08 16:49:15 +05'30'

Dharamvir Malik
Company Secretary & Compliance Officer

Encl: As Above

Registered Office
304, Mohan Place, L.S.C., Block-C, Saraswati Vihar, New Delhi-110034 (INDIA).
+91-11-47511000 +91-11-27023256

Akums reports robust Q1 FY27 performance with 13.9% YoY Revenue growth

New Delhi, August 2026: Akums Drugs and Pharmaceuticals Ltd., India's largest Contract Development and Manufacturing Organization (CDMO), announced its consolidated financial results for the quarter ended June 30, 2026, marking a strong start to FY27. The Company delivered healthy growth in revenue, operating profitability and PAT, supported by continued momentum in its CDMO business, improved operating performance and healthy customer demand.

Akums reported operating revenue of ₹1,167 crore in Q1 FY27, registering a 13.9% year-on-year growth compared with ₹1,024 crore in Q1 FY26. EBITDA increased 35.4% year-on-year to ₹175 crore, with EBITDA margin improving to 15.0% from 12.6%. PAT stood at ₹101 crore, compared with ₹65 crore in the corresponding quarter last year. PAT margin also improved to 8.4% from 6.2%.

The CDMO business remained the key growth driver during the quarter. CDMO revenue increased to ₹964 crore, compared with ₹813 crore in Q1 FY26, while CDMO EBITDA grew 36.8% year-on-year to ₹163 crore from ₹119 crore in Q1 FY26, supported by continued volume growth and improvement in API prices.

Commenting on the results, **Mr. Sanjeev Jain, Managing Director**, said, *"FY27 has begun on a strong and encouraging note. The consistent performance of CDMO showcases healthy demand environment as well as our clients' trust in Akums as the preferred manufacturing partner."*

Mr. Sandeep Jain, Managing Director, added, *"We remain focused on strengthening our CDMO leadership, scaling high-value capabilities, and driving operational excellence. Backed by a strong pipeline and prudent capital allocation, we are well-positioned to deliver sustainable growth in the years ahead."*

Extract of Consolidated financial results

Particulars (Rs Cr)	**Q1 FY 27**	**Q4 FY 26**	**Q1 FY 26**
Revenue	**1,167**	**1,158**	**1,024**
Cost of goods sold	645	660	582
Employee Cost	201	199	176
Other Expenses	145	147	137
EBITDA	**175**	**152**	**129**
EBITDA Margin	**15.0%**	**13.1%**	**12.6%**
PAT	**101**	**81**	**65**
PAT Margin	**8.4%**	**6.8%**	**6.2%**

For further information, please contact:
IR Desk
investors@akums.net/ankit.jain@akums.net